Plain-English translation of NCT06980597 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing whether , a type of cell therapy that uses your own modified immune cells, can help people with severe autoimmune diseases like lupus, inflammatory muscle disease, scleroderma, or vasculitis. These are diseases where the immune system mistakenly attacks the body's own tissues. The study will enroll 44 participants and evaluate whether this medication is safe, how it moves through the body, and whether it actually reduces disease activity.
Standard treatments for these autoimmune diseases don't work well enough for many patients—some people's diseases keep getting worse despite current medications. This study exists to explore whether this new approach using specially processed immune cells might offer hope for people whose autoimmune disease is resistant to conventional therapies.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive the cell therapy treatment, which involves several steps: first, a conditioning regimen to prepare your body, then infusion of the specially processed immune cells. You would then be closely monitored through clinic visits and blood tests to check how safe the medication is, how your body processes it, and whether your disease improves. The study would track your health and symptoms over time, with regular follow-up appointments to assess your response to treatment.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Beijing GoBroad Hospital
Enrollment target
~44 participants
Started
June 2025
Primary completion
December 2027
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kai Hu
Beijing GoBroad Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.